Page last updated: 2024-10-21

n-methyl-3,4-methylenedioxyamphetamine and Stevens-Johnson Syndrome

n-methyl-3,4-methylenedioxyamphetamine has been researched along with Stevens-Johnson Syndrome in 1 studies

N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.

Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wetzel, M1
Surkhabi, W1
Jung, JY1

Other Studies

1 other study available for n-methyl-3,4-methylenedioxyamphetamine and Stevens-Johnson Syndrome

ArticleYear
Stevens-Johnson syndrome/toxic epidermal necrolysis associated with ecstasy exposure.
    The Australasian journal of dermatology, 2020, Volume: 61, Issue:3

    Topics: Adult; Female; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Stevens-Johnson Syndro

2020